The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1707
July 22, 2024
View Complete Issue         Table of Contents 2019 
Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections
July 22, 2024 (Issue: 1707)
The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract infections (cUTIs), including...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections
Article code: 1707d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.